Why Oracle Corporation (ORCL) Overspent on Acme Packet, Inc. (APKT)

Page 1 of 2

Shares of Acme Packet, Inc. (NASDAQ:APKT) have surged 68% over the past three months since reaching a low of $15.31 in late October. Clearly investors were placing huge bets ahead of the company’s Q4 earnings report released Monday. But what they got was a surprise buyout by Oracle Corporation (NASDAQ:ORCL) for $2.1 billion. And with telecoms ravaged by poor carrier spending, it’s not yet clear that Acme Packet deserved this premium.

Oracle (ORCL)Absent clear signs that spending will rebound, it doesn’t justify the optimism in Acme Packet. Besides, with a P/E ratio well over 300, it’s fair to ask where the value is. Although Acme Packet has a sizable lead in the session delivery market, it pales in comparison to Cisco Systems, Inc. (NASDAQ:CSCO), which has a superior portfolio. And for value investors, Cisco also comes with much less risk.

Disappointing fourth quarter, but it’s Oracle’s problem now
While the Q4 report would have been the perfect starting point to this relationship. Acme Packet’s results made me question whether or not Oracle truly knows what it’s getting itself into. Granted, Acme Packet issued a warning to investors that the results would be light, saying revenue would arrive in the range of $84 million to $86 million, with earnings coming in at $0.26-$0.28 per share.

Granted, both targets were well below Street estimates. But the numbers were consistent with the outlook given by rivals. I was nonetheless shocked by what the company actually reported. Revenue dropped 15% year over year to $70.7 million. This was well below the low end of the company’s own revenue estimates of $84 million. Never mind that it missed the consensus projections of $93.4 million

Non-GAAP net income dropped 64% to $6.5 million, or $0.09 per share. Essentially, not only did Acme Packet miss its own prior EPS estimates by 65%, but the company managed to also miss revenue estimates by 16%. Now these are pretty wide margins of error — even for a lemonade stand.

Then again, not much was expected seeing as carriers have yet to open their wallets, which was evident in ADTRAN, Inc. (NASDAQ:ADTN)‘s fourth-quarter earnings report. The good news for Acme Packet is that Adtran’s results were broadly in line with estimates with earnings arriving at $4 million, or $0.06 per share. Then again, for Adtran, both net income and revenue dropped 87% and 20%, respectively.

By comparison, Ciena Corporation (NASDAQ:CIEN) didn’t woo the Street with its 2% revenue growth, but unlike Acme Packet, there is evidence that the company has begun to turn things around. Despite Ciena’s soft report, shares jumped 5%. For Ciena, its solid fundamentals continue to reassure investors of its sound management.

Essentially, the Street believes Ciena’s soft numbers were the result of macro conditions and not a lack of execution. That’s not the case with Acme Packet. Plus, the Street was pleased with how Ciena performed categorically, including 66% growth in carrier Ethernet service delivery, or CESD. Likewise, service revenue soared 21%. And even with the half-point-drop in gross margin, it rose sequentially by over 3 points.

Essentially, in Ciena’s situation, it’s hard to punish the company for reporting earnings that merely arrive in-line with estimates, particularly in tough macro climates. However, when the stock carries a valuation multiple 20 times the industry standard, as Acme Packet does, the scrutiny is warranted — especially when cheaper rivals outperform.

Then again, it’s reasonable to suspect that Acme Packet knew the importance of its guidance as it was negotiating its deal with Oracle. Guiding too low would have sent investors into a panic, potentially shedding valuable negotiating leverage. On the other hand, there’s no way Oracle would have done this deal without prior due diligence. Oracle is too smart.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!